Information for use, read carefully!
Name of the product: OLIMUNOVAC®
1 capsule contains 9 mg of active substance, prepared by lyophilisation of inactivated microorganisms:
Staphylococcus aureus lysatum cryodessicatum (CCM 7587)
Klebsiella pneumoniae lysatum cryodessicatum (CCM 7589)
Propionibacterium acnes lysatum cryodessicatum (CCM 7083)
Expicients: silica, lactose, potato starch (fillers).
Characteristics and field of use:
OLIMUNOVACis produced with the most up-to-date biotechnological and purification technologies. It contains a unique combination of purified lysates (highly purified harmless parts of inactivated microorganisms) of three original, patented bacterial strains.
The application form of the preparation is an oral capsule.
OLIMUNOVAC may be used with advantage as a part of the measures in a period of increased occurrence of respiratory tract infections.
Do not use in the case of hypersensitivity to any of the product’s components.
Not known. The preparation is produced from natural materials.
Not known. Simultaneous administration with immunobiological products is not recommended. Consultation with a physician is always necessary in these cases.
Posology and method of administration:
The basic treatment – 4 five-day cycles of 1 capsule per day, best in the morning on empty stomach with five-day interruptions; after 25 days of interruption, 2 maintenance five-day cycles with 25-day interruption.
At the end of this basic cycle of the OLIMUNOVAC® use, it is possible to continue with this dosage after a repeated 25-day interruption. In order to achieve a longer-lasting effect, the product may also be used more times per year after an advice of your physician.
|1. month||2. month||3. month||4. month|
Intended for use in children from the age of 3 years and in adults. Consult your physician if the product should be used in pregnant and breast-feeding women.
Do not exceed the recommended daily dose.
The product is not intended as a replacement of rich diet.
Shelf life is provided on the cover.
Keep out of the reach of children.
Under a temperature to 25oC, in dry and dark place.
Bioveta, a.s., Medical Department, Komenského 212, 683 23 Ivanovice na Hané.
Produced under pharmaceutical supervision and control.
Developed in cooperation with the Medical Faculty of the Palacky University in Olomouc.
References: Petřek M.,Weigl E.,Bystroň J.,et al.:Study of immunomodulating effects of Olimunostim on cellular immunity in healthy humans. Acta Univ. Palacki. Olomuc. Fac. Med. 134,1992,p.286-291.
Bystroň J.: Perorální bakteriální imunomodulátory a medicína založená na důkazech. Alergie 5, 2003, 284-290.